• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eurosurv. Mid-season real-time estimates of seasonal influenza vaccine effectiveness in persons 65 years and older in register-based surveillance, Sto

tetano

Editor, Senior Moderator
Eurosurveillance, Volume 22, Issue 8, 23 February 2017
Research article

Mid-season real-time estimates of seasonal influenza vaccine effectiveness in persons 65 years and older in register-based surveillance, Stockholm County, Sweden, and Finland, January 2017


M Hergens [SUP]1[/SUP] [SUP]2[/SUP] , U Baum [SUP]2[/SUP] [SUP]3[/SUP] , M Brytting [SUP]4[/SUP] , N Ikonen [SUP]5[/SUP] , A Haveri [SUP]5[/SUP] , ? Wiman [SUP]4[/SUP] , H Nohynek [SUP]2[/SUP] [SUP]6[/SUP] , ? ?rtqvist [SUP]1[/SUP] [SUP]2[/SUP]
+ Author affiliations
1. Department of Communicable Disease Control and Prevention, Stockholm County Council, and Karolinska Institutet, Department of Medicine Karolinska Solna, Unit of Infectious Diseases, Stockholm, Sweden
2. These authors contributed equally to this work
3. Impact Assessment Unit, Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland
4. Unit for laboratory surveillance of viral pathogens and vaccine preventable diseases, Department of Microbiology, The Public Health Agency of Sweden, Solna, Sweden
5. Viral Infections Unit, Department of Health Security, National Institute for Health and Welfare, Helsinki, Finland
6. Vaccination Programme Unit, Department of Health Security, National Institute for Health and Welfare, Helsinki, Finland


Correspondence: ?ke ?rtqvist (ake.ortqvist@sll.se)








Citation style for this article: Hergens M, Baum U, Brytting M, Ikonen N, Haveri A, Wiman ?, Nohynek H, ?rtqvist ?. Mid-season real-time estimates of seasonal influenza vaccine effectiveness in persons 65 years and older in register-based surveillance, Stockholm County, Sweden, and Finland, January 2017. Euro Surveill. 2017;22(8):pii=30469. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2017.22.8.30469

Received:08 February 2017; Accepted:20 February 2017

[h=4][/h]
Systems for register-based monitoring of vaccine effectiveness (VE) against laboratory-confirmed influenza (LCI) in real time were set up in Stockholm County, Sweden, and Finland, before start of the 2016/17 influenza season, using population-based cohort studies. Both in Stockholm and Finland, an early epidemic of influenza A(H3N2) peaked in week 52, 2016. Already during weeks 48 to 50, analyses of influenza VE in persons 65 years and above showed moderately good estimates of around 50%, then rapidly declined by week 2, 2017 to 28% and 32% in Stockholm and Finland, respectively. The sensitivity analyses, where time since vaccination was taken into account, could not demonstrate a clear decline, neither by calendar week nor by time since vaccination. Most (68%) of the samples collected from vaccinated patients belonged to the 3C.2a1 subclade with the additional amino acid substitution T135K in haemagglutinin (64%) or to subclade 3C.2a with the additional haemagglutinin substitutions T131K and R142K (36%). The proportion of samples containing these alterations increased during the studied period. These substitutions may be responsible for viral antigenic change and part of the observed VE drop. Another possible cause is poor vaccine

full article

http://eurosurveillance.org/ViewArticle.aspx?ArticleId=22723
 
Back
Top Bottom